Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LITESPARK-003: Belzutifan + Cabozantinib in Advanced ccRCC
NCT03634540Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2018
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belzutifan in clear cell renal cell carcinoma (ccRCC), sponsored by Merck & Co.. Started Sep 2018; status: active, not recruiting.
02
Drugs
belzutifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03634540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634540.